Review Special Issue Series: T-cell Based Vaccine Development against Pathogen Infections
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Innate and Adaptive Immunity in Vaccination".
Deadline for manuscript submissions: 31 December 2024 | Viewed by 5367
Special Issue Editor
Interests: cross-neutralization of SARS-CoV-2 kappa and delta variants by inactivated vaccine-elicited serum and monoclonal antibodies
Special Issue Information
Dear Colleagues,
Current COVID-19 vaccines are designed to induce neutralizing antibodies against SARSCoV-2, which wane over time and are usually evaded by highly infectious variants such as Omicron. T cells play an important role in protection against viral infection. SARS-CoV-2-specific T cells induced during infection or vaccination largely maintained their reactivity to viral variants, including Omicron, indicating T cell responses are critical for long-term protective immunity. Thus, the development of T-cell-based vaccines that are able to induce long-term memory T cells might be a reasonable and effective strategy to provide persistent protection against constantly mutating viruses, including SARS-CoV-2. This Special Issue will broadly cover the topics related to T-cell-based vaccines. The interests of this Special Issue include, but are not limited to: (1) dynamics and functionality of T cell response to viruses including SARS-CoV-2, (2) dominant T cell epitopes in various viruses such as SARS-CoV-2, (3) generation and maintenance of long-term memory T cells, and (4) animal models for evaluation of the immunogenicity and efficacy of T-cell-based vaccines designed for humans.
Prof. Dr. Zheng Zhang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- T cell
- T-cell-based vaccine
- T cell response
- immune response
- SARS-CoV-2
- COVID-19 vaccine
- animal model
- immunogenicity
- efficacy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
